<DOC>
	<DOCNO>NCT01777581</DOCNO>
	<brief_summary>This study investigate whether milnacipran reduces radicular pain ( `` sciatica '' ) patient lumbosacral disc disease .</brief_summary>
	<brief_title>Milnacipran Lumbosacral Radicular Pain</brief_title>
	<detailed_description>The current study evaluate potential efficacy milnacipran reduce low extremity radicular pain associated lumbar disk disease . Milnacipran titrate base efficacy tolerability aim high end therapeutic range ; recent study serotonin norepinephrine reuptake inhibitor patient osteoarthritis pain suggests efficacy may dose related . Patients likely concomitant nociceptive low back pain , cotreatment opioids , muscle relaxant , benzodiazepine , nonsteroidal anti-inflammatory drug stable dos permit . Patients participate stable regimen physical therapy biofeedback eligible . Procedural intervention ( e.g . epidural steroid injection , nerve block , facet radioablation , acupuncture ) study 3 month prior exclusionary . Anticonvulsants , tramadol , antidepressant drug exclude . The study ten-week randomize , double-blind , placebo-controlled trial ( RCT ) milnacipran ( 100-200 mg/day dose twice day ) radicular pain associated lumbosacral disk disease . Outcome measure safety assessment obtain week 1 , 2 , 4 , 6 , 8 , 10 accord protocol schedule assessment .</detailed_description>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>1 . Subject male female adult outpatient age 18 old time consent . 2 . Subject experience chronic ( &gt; 6 month ) radicular pain least 5 day week describe sharp shooting level knee associate lumbar sacral disk disease without suspicion recent injury ; remote ( &gt; 1 year ago ) history surgical intervention ( e.g . `` fail back syndrome '' ) allow provide current symptom meet severity criterion . 3 . Subjectrated VAS specifically relate radicular pain &gt; = 40 mm screen baseline visit 4 . Subject understanding , ability willingness fully comply study procedure restriction . 5 . Subject ability provide write , personally sign date informed consent participate study , accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guideline E6 applicable regulation , complete studyrelated procedure . 1 . Subjects unable complete assessment due language cognitive impairment 2 . Subjects treat antidepressant anticonvulsant medication within 4 week screen visit ( 6 week fluoxetine ) . 3 . Subjects take monoamine oxidase inhibitor 4 . Subjects receive procedural intervention within 3 month screen . 5 . Subjects know sensitivity milnacipran . 6 . Subjects unable complete questionnaire due language cognitive impairment . 7 . Subjects history bipolar disorder psychosis confirm Mini International Neuropsychiatric Interview ( MINI ) . 8 . Subject currently ( history within last 6 month ) drug dependence substance abuse disorder accord Diagnostic Statistical Manual Mental Disorders , Text Revision criterion ( exclude nicotine ) . 9 . Subjects currently consider suicide risk , subject previously make suicide attempt prior history currently demonstrate active suicidal ideation . 10 . Subject clinically significant electrocardiogram ( ECG ) clinically significant laboratory abnormality ( include positive urine drug screen ) Screening . 11 . Subject concurrent chronic acute illness , disability , condition might confound result safety assessment administer study might increase risk subject . Similarly , subject exclude additional condition ( ) Investigator 's opinion would prohibit subject completing study would best interest subject . This would include significant illness unstable medical condition could lead difficulty comply protocol . 12 . Subjects pregnant nursing 13 . Subjects agree use adequate reliable contraception throughout study . 14 . Subject previously complete , discontinue withdrawn study . 15 . Subject take investigational drug take part clinical trial within 30 day prior Screening . 16 . Subjects liver disease reduce liver function 17 . Subjects obstructive uropathy 18 . Subjects consume alcohol amount view Investigator contraindicate 19 . Subjects uncontrolled narrow angle glaucoma 20 . Subjects seizure disorder 21 . Subjects bleed disorder use medication may cause bleed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>sciatica radiculopathy lumbar disc lumbosacral disc</keyword>
</DOC>